Evidence map›Paper›PMID 41616263›Full record

ArticleAntimicrobial agents and chemotherapy2026

Evaluation of an

Alex Lepak, Sujata M Bhavnani, Mariana Castanheira, Christopher M Rubino, Jeffrey P Hammel, M Courtney Safir, Justin Massey, William Hartman, Paul Ambrose, David Andes

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Alex LepakUniversity of Wisconsin, Madison, Wisconsin, USA.
Sujata M BhavnaniInstitute for Clinical Pharmacodynamics, Schenectady, New York, USA.ORCID 0000-0003-4891-6467
Mariana CastanheiraElement, North Liberty, Iowa, USA.
Christopher M RubinoInstitute for Clinical Pharmacodynamics, Schenectady, New York, USA.ORCID 0000-0003-3172-0847
Jeffrey P HammelInstitute for Clinical Pharmacodynamics, Schenectady, New York, USA.
M Courtney SafirInstitute for Clinical Pharmacodynamics, Schenectady, New York, USA.ORCID 0000-0003-0452-682X
Justin MasseyUniversity of Wisconsin, Madison, Wisconsin, USA.
William HartmanUniversity of Wisconsin, Madison, Wisconsin, USA.
Paul AmbroseInstitute for Clinical Pharmacodynamics, Schenectady, New York, USA.ORCID 0000-0002-2230-1125
David AndesUniversity of Wisconsin, Madison, Wisconsin, USA.ORCID 0000-0002-7927-9950

Funding

U.S. Food and Drug Administration 75F40123C00143
6 · The paper itself

Abstract

Use of mouse infection models for antimicrobial pharmacokinetic/pharmacodynamic (PK/PD) analysis can assist in dosing regimen design and susceptibility breakpoint development. A major hurdle for clinical translation of

Indexed as

Antifungal AgentsAspergillus fumigatusPulmonary AspergillosisTriazolesAnimalsDisease Models, AnimalDrug Resistance, FungalFemaleHumansMiceMicrobial Sensitivity TestsAntifungal AgentsposaconazoleTriazolesAspergillusbreakpointPK/PDposaconazole

Identifiers

PMID41616263
PMCPMC12959153

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.